Will you be attending the World Vaccine Congress in April 2018? Meet with representatives from VGXI at Booth # 212 and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. Still need to register? Join VGXI at WVC 2018 using the discount code… Read More »
As a leading GMP manufacturer of high quality plasmid DNA, VGXI, Inc. has been recognized in the final shortlist of companies for the category of “Best Contract Manufacturing Organization (CMO)” for the 2018 Vaccine Industry Excellence Awards. Click here to view the full list of finalists for the ViE Awards Will you be attending the World… Read More »
Texas based plasmid CMO VGXI breaks ground on facility expansion and new flex-scale GMP production plants. The Woodlands, TX – February 22, 2018 – VGXI announced today they have broken ground on a 5,000 square foot expansion of their Texas based manufacturing facility. Once complete, the project will increase the company’s footprint… Read More »
Will you be attending the Phacilitate conference in January 2018? Meet with representatives from VGXI at booth # 714 and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements.
Nominations are now open for the Vaccine Industry Excellence Awards of the 2018 World Vaccine Congress this April! Show your support for VGXI, Inc. by nominating us for the categories of “Best CMO” and “Best Production/Process Development“. Submit your nominations at the following link by 12Jan18: http://www.terrapinn.com/conference/world-vaccine-congress-washington/2018-ViE-Awards-Categories.stm
The Woodlands, TX, January 03, 2018: Learn more about Dorothy Peterson, VGXI’s VP of Operations, in a newly released publication by Voyage Houston Magazine. Follow this link to the full article: http://voyagehouston.com/interview/meet-dorothy-peterson-vgxi-inc-2700-research-forest-drive-suite-180-woodlands-tx-77381/
Stability of Plasmid DNA Products: A Review of the Data For any pharmaceutical product, an important consideration is the handling and environmental conditions that the material may experience from the time it is manufactured until final dosing of a patient. Plasmid DNA is generally recognized to have exceptional stability compared to other… Read More »
Calculating the amount of plasmid DNA needed for a clinical trial may seem straightforward – simply multiply the dose by the number of doses to be administered. However, there are many factors to consider, and the required production scale may be several times the amount needed for clinical dosing. This white paper walks through one case study to illustrate… Read More »
GeneOne Life Science Receives Approval of IND by the Korean Ministry of Food and Drug Safety (KMFDS) of MERS-CoV Plasmid DNA vaccine, GLS-5300, for a Phase I/IIa Clinical Trial in Korea SEOUL, KOREA (PRWEB) September 17, 2017 GeneOne Life Science, Inc. announces that it has received approval from the South Korean Ministry of… Read More »
VGXI has reopened and we are getting back to normal operations. Our thoughts are with all those who have been affected by Hurricane Harvey, including our employees, their families, and all our neighbors in the area. For any who would like to contribute to the recovery effort, please consider a donation to… Read More »
Update: VGXI will open for business on Thursday, August 31, 2017. To ensure the safety of our employees and their families, VGXI closed from Monday through Wednesday, August 28th – 30th, 2017. Please stay safe and check back on our website or facebook page for updates.
Heading to Paris in October? Meet with representatives from VGXI and learn more about our products and services! We also welcome requests for partnering meetings during the conference. Contact Us today to make arrangements. 2017 International Society of Vaccines Annual Congress October 5 – 7, 2017 Institute Pasteur Paris, France
For more information